QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
Log in
OTCMKTS:IPCIF

Intellipharmaceutics International Competitors

$0.19
-0.01 (-7.27 %)
(As of 10/21/2020 12:48 PM ET)
Add
Compare
Today's Range
$0.19
Now: $0.19
$0.21
50-Day Range
$0.09
MA: $0.13
$0.22
52-Week Range
$0.06
Now: $0.19
$0.95
Volume27,205 shs
Average Volume105,774 shs
Market Capitalization$4.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76

Competitors

Intellipharmaceutics International (OTCMKTS:IPCIF) Vs. RGLS, AEZS, NVUS, GHSI, EYEG, and DMPI

Should you be buying IPCIF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Intellipharmaceutics International, including Regulus Therapeutics (RGLS), Aeterna Zentaris (AEZS), Novus Therapeutics (NVUS), Guardion Health Sciences (GHSI), Eyegate Pharmaceuticals (EYEG), and DelMar Pharmaceuticals (DMPI).

Intellipharmaceutics International (OTCMKTS:IPCIF) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.

Volatility and Risk

Intellipharmaceutics International has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.

Profitability

This table compares Intellipharmaceutics International and Regulus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellipharmaceutics International-232.11%N/A-84.85%
Regulus Therapeutics-35,448.34%-214.08%-72.34%

Earnings & Valuation

This table compares Intellipharmaceutics International and Regulus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics International$3.48 million1.29$-8,090,000.00N/AN/A
Regulus Therapeutics$6.83 million2.83$-18,590,000.00($1.08)-0.49

Intellipharmaceutics International has higher earnings, but lower revenue than Regulus Therapeutics.

Insider and Institutional Ownership

17.6% of Regulus Therapeutics shares are held by institutional investors. 18.2% of Regulus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Intellipharmaceutics International and Regulus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellipharmaceutics International0000N/A
Regulus Therapeutics02102.33

Regulus Therapeutics has a consensus price target of $1.25, indicating a potential upside of 134.96%. Given Regulus Therapeutics' higher probable upside, analysts clearly believe Regulus Therapeutics is more favorable than Intellipharmaceutics International.

Summary

Regulus Therapeutics beats Intellipharmaceutics International on 9 of the 12 factors compared between the two stocks.

Aeterna Zentaris (NASDAQ:AEZS) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Aeterna Zentaris and Intellipharmaceutics International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeterna Zentaris0000N/A
Intellipharmaceutics International0000N/A

Profitability

This table compares Aeterna Zentaris and Intellipharmaceutics International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeterna Zentaris-274.71%N/A-20.30%
Intellipharmaceutics International-232.11%N/A-84.85%

Volatility and Risk

Aeterna Zentaris has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500.

Insider & Institutional Ownership

2.3% of Aeterna Zentaris shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Aeterna Zentaris and Intellipharmaceutics International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeterna Zentaris$530,000.0035.89$-6,040,000.00N/AN/A
Intellipharmaceutics International$3.48 million1.29$-8,090,000.00N/AN/A

Aeterna Zentaris has higher earnings, but lower revenue than Intellipharmaceutics International.

Intellipharmaceutics International (OTCMKTS:IPCIF) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Profitability

This table compares Intellipharmaceutics International and Novus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellipharmaceutics International-232.11%N/A-84.85%
Novus TherapeuticsN/A-145.07%-126.53%

Institutional & Insider Ownership

31.4% of Novus Therapeutics shares are held by institutional investors. 5.6% of Novus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Intellipharmaceutics International has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Intellipharmaceutics International and Novus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellipharmaceutics International0000N/A
Novus Therapeutics02102.33

Novus Therapeutics has a consensus target price of $35.10, suggesting a potential upside of 104.90%. Given Novus Therapeutics' higher probable upside, analysts plainly believe Novus Therapeutics is more favorable than Intellipharmaceutics International.

Valuation & Earnings

This table compares Intellipharmaceutics International and Novus Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics International$3.48 million1.29$-8,090,000.00N/AN/A
Novus TherapeuticsN/AN/A$-16,010,000.00($21.58)-0.79

Intellipharmaceutics International has higher revenue and earnings than Novus Therapeutics.

Summary

Novus Therapeutics beats Intellipharmaceutics International on 7 of the 11 factors compared between the two stocks.

Guardion Health Sciences (NASDAQ:GHSI) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Guardion Health Sciences and Intellipharmaceutics International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Guardion Health Sciences$900,000.0019.78$-10,880,000.00N/AN/A
Intellipharmaceutics International$3.48 million1.29$-8,090,000.00N/AN/A

Intellipharmaceutics International has higher revenue and earnings than Guardion Health Sciences.

Analyst Ratings

This is a summary of current ratings and recommmendations for Guardion Health Sciences and Intellipharmaceutics International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Guardion Health Sciences0000N/A
Intellipharmaceutics International0000N/A

Institutional & Insider Ownership

2.2% of Guardion Health Sciences shares are held by institutional investors. 3.9% of Guardion Health Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Guardion Health Sciences has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500.

Profitability

This table compares Guardion Health Sciences and Intellipharmaceutics International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Guardion Health Sciences-517.42%-81.72%-74.32%
Intellipharmaceutics International-232.11%N/A-84.85%

Summary

Intellipharmaceutics International beats Guardion Health Sciences on 5 of the 9 factors compared between the two stocks.

Eyegate Pharmaceuticals (NASDAQ:EYEG) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Eyegate Pharmaceuticals and Intellipharmaceutics International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eyegate PharmaceuticalsN/A-135.39%-93.03%
Intellipharmaceutics International-232.11%N/A-84.85%

Analyst Recommendations

This is a summary of current recommendations for Eyegate Pharmaceuticals and Intellipharmaceutics International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eyegate Pharmaceuticals00203.00
Intellipharmaceutics International0000N/A

Eyegate Pharmaceuticals currently has a consensus price target of $10.75, suggesting a potential upside of 183.27%. Given Eyegate Pharmaceuticals' higher probable upside, research analysts clearly believe Eyegate Pharmaceuticals is more favorable than Intellipharmaceutics International.

Valuation & Earnings

This table compares Eyegate Pharmaceuticals and Intellipharmaceutics International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eyegate Pharmaceuticals$2.69 million6.53$-7,100,000.00($2.23)-1.70
Intellipharmaceutics International$3.48 million1.29$-8,090,000.00N/AN/A

Eyegate Pharmaceuticals has higher earnings, but lower revenue than Intellipharmaceutics International.

Institutional and Insider Ownership

42.2% of Eyegate Pharmaceuticals shares are held by institutional investors. 57.0% of Eyegate Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Eyegate Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500.

Summary

Eyegate Pharmaceuticals beats Intellipharmaceutics International on 8 of the 12 factors compared between the two stocks.

Intellipharmaceutics International (OTCMKTS:IPCIF) and DelMar Pharmaceuticals (NASDAQ:DMPI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Institutional & Insider Ownership

1.3% of DelMar Pharmaceuticals shares are held by institutional investors. 5.7% of DelMar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Intellipharmaceutics International and DelMar Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics International$3.48 million1.29$-8,090,000.00N/AN/A
DelMar PharmaceuticalsN/AN/A$-8,050,000.00($3.16)-0.48

DelMar Pharmaceuticals has lower revenue, but higher earnings than Intellipharmaceutics International.

Profitability

This table compares Intellipharmaceutics International and DelMar Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellipharmaceutics International-232.11%N/A-84.85%
DelMar PharmaceuticalsN/AN/A-131.37%

Risk and Volatility

Intellipharmaceutics International has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, DelMar Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Intellipharmaceutics International and DelMar Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellipharmaceutics International0000N/A
DelMar Pharmaceuticals00103.00

DelMar Pharmaceuticals has a consensus price target of $2.00, suggesting a potential upside of 31.58%. Given DelMar Pharmaceuticals' higher possible upside, analysts plainly believe DelMar Pharmaceuticals is more favorable than Intellipharmaceutics International.

Summary

DelMar Pharmaceuticals beats Intellipharmaceutics International on 8 of the 10 factors compared between the two stocks.


Intellipharmaceutics International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Regulus Therapeutics logo
RGLS
Regulus Therapeutics
1.5$0.53-3.8%$19.36 million$6.83 million-0.55Decrease in Short Interest
Aeterna Zentaris logo
AEZS
Aeterna Zentaris
0.6$0.36-0.0%$19.02 million$530,000.00-1.98
Novus Therapeutics logo
NVUS
Novus Therapeutics
1.3$17.13-0.8%$18.47 millionN/A-0.82Analyst Downgrade
GHSI
Guardion Health Sciences
0.5$0.20-0.0%$17.80 million$900,000.000.00Decrease in Short Interest
Eyegate Pharmaceuticals logo
EYEG
Eyegate Pharmaceuticals
1.8$3.80-0.5%$17.56 million$2.69 million-1.40Heavy News Reporting
DelMar Pharmaceuticals logo
DMPI
DelMar Pharmaceuticals
1.3$1.52-2.0%$17.41 millionN/A-1.07
GTBP
GT Biopharma
0.5$0.23-4.3%$17.29 millionN/A0.00High Trading Volume
Heavy News Reporting
IntelGenx Technologies logo
IGXT
IntelGenx Technologies
1.2$0.15-6.5%$17.07 million$740,000.00-0.62Heavy News Reporting
Mateon Therapeutics logo
MATN
Mateon Therapeutics
0.8$0.19-0.0%$17.02 millionN/A0.00
Intec Pharma logo
NTEC
Intec Pharma
0.6$0.23-0.0%$16.67 millionN/A-0.25
SLRX
Salarius Pharmaceuticals
2.1$0.83-3.6%$16.35 million$3.46 million-0.39Increase in Short Interest
ULUR
ULURU
0.3$0.79-12.7%$15.99 million$720,000.000.00
Tetraphase Pharmaceuticals logo
TTPH
Tetraphase Pharmaceuticals
1.6$2.20-0.0%$15.98 million$7.38 million-0.12
Sonoma Pharmaceuticals logo
SNOA
Sonoma Pharmaceuticals
0.5$7.78-2.8%$15.72 million$18.94 million-4.18
Bio-Path logo
BPTH
Bio-Path
1.5$4.09-0.7%$15.10 million$40,000.00-1.39Analyst Downgrade
INBP
Integrated BioPharma
1.1$0.47-0.0%$13.94 million$52.77 million5.88
Novelion Therapeutics logo
NVLN
Novelion Therapeutics
0.5$0.70-0.0%$13.77 million$130.43 million0.00Heavy News Reporting
NVLNF
Novelion Therapeutics
0.7$0.70-1.2%$13.77 million$130.43 million0.00
Mallinckrodt logo
MNK
Mallinckrodt
2.0$0.16-6.4%$13.23 million$3.16 billion-0.01
MYOS
MYOS RENS Technology
0.7$1.06-11.3%$12.92 million$1.03 million-2.86
PHIO
Phio Pharmaceuticals
2.1$2.21-5.0%$12.77 million$20,000.00-0.21Heavy News Reporting
WCUI
Wellness Center USA
0.5$0.10-0.0%$10.96 million$30,000.000.00
SXTC
China SXT Pharmaceuticals
0.4$0.31-9.6%$10.83 million$5.16 million0.00High Trading Volume
Heavy News Reporting
EMBI
OTCMKTS:EMBI
0.5$0.04-0.0%$10.30 millionN/A-0.52
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04-25.5%$10.14 million$7.38 million0.00
XTLB
X T L Biopharmaceuticals
0.6$2.35-1.3%$10 millionN/A-3.79
REXN
Rexahn Pharmaceuticals
0.6$2.15-1.9%$9.64 millionN/A0.00
ANCN
Anchiano Therapeutics
1.2$1.16-27.6%$8.61 millionN/A-0.66High Trading Volume
Heavy News Reporting
AMAR
Amarillo Biosciences
1.1$0.20-0.0%$8.18 million$10,000.000.00Heavy News Reporting
NRIFF
Nuvo Pharmaceuticals
0.9$0.69-4.4%$7.81 million$52.41 million2.21Heavy News Reporting
VIVUS logo
VVUS
VIVUS
1.2$0.42-2.4%$7.43 million$69.76 million-0.15
Medicure logo
MCUJF
Medicure
0.6$0.64-0.0%$6.84 million$15.20 million-0.53Heavy News Reporting
ABMC
American Bio Medica
0.5$0.20-3.9%$6.56 million$3.65 million0.00
RELV
Reliv International
0.7$3.62-1.9%$6.32 million$35.06 million-32.91Decrease in Short Interest
Auris Medical logo
EARS
Auris Medical
0.6$0.89-2.2%$6.31 millionN/A-0.39
KAYS
Kaya
0.8$0.03-0.0%$5.96 million$1.01 million0.00Heavy News Reporting
Teligent logo
TLGT
Teligent
1.2$1.05-32.5%$5.63 million$65.90 million-0.11High Trading Volume
Xenetic Biosciences logo
XBIO
Xenetic Biosciences
1.5$0.88-3.4%$5.61 million$20,000.000.00Increase in Short Interest
Heavy News Reporting
NMUS
Nemus Bioscience
0.6$0.04-0.0%$5.52 millionN/A0.00
ICOTF
iCo Therapeutics
0.5$0.04-0.0%$5.43 millionN/A-1.77Heavy News Reporting
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.24-17.0%$5.09 million$2.66 million-23.51
ISCO
International Stem Cell
0.7$0.61-3.3%$4.75 million$9.47 million0.00
SNNA
Sienna Biopharmaceuticals
0.7$0.14-0.0%$4.20 millionN/A-0.04High Trading Volume
Innovus Pharmaceuticals logo
INNV
Innovus Pharmaceuticals
1.2$1.23-5.7%$3.94 million$23.99 million-0.38Heavy News Reporting
RSPI
Respirerx Pharmaceuticals
0.5$0.01-22.8%$3.52 millionN/A-0.01High Trading Volume
BNTC
Benitec Biopharma
1.2$2.95-1.4%$3.27 million$100,000.00-0.36High Trading Volume
WIZP
Wize Pharma
0.6$0.17-15.1%$3.10 millionN/A-0.38
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72
GOVX
GeoVax Labs
1.2$3.23-3.4%$2.49 million$1.18 million0.00High Trading Volume
FTCY
Global Future City
0.5N/AN/A$2.45 millionN/A0.00
This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.